Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis. (PREVIMUC)

Civil Hospices of Lyon

Status: Completed

Conditions: Cystic Fibrosis; Respiratory Viral Infection

Treatments: Other: Physical assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT02847156

69HCL14_0276

Details and patient eligibility

About

Respiratory Viral Infections (RVI) are particularly frequent in young children. Old data mention the deleterious role of some viruses such as the Respiratory Syncytial Virus in young children with cystic fibrosis (CF). However, recent epidemiological data on RVI in CF children are rare and the impact of most frequent viruses such as human rhinoviruses is usually not correctly evaluated.

The aim of this study is to assess the frequency of lower and upper RVI during a 1 year follow-up in CF infants and to evaluate the impact of RVI at a clinical, microbiological and therapeutic level.

Our hypothesis is that frequent and/or clinically severe RVIs have the worst impact in the short term and without any particular link with a specific virus as previously described.

Enrollment: 25 patients

Sex: All

Ages: Under 24 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• infant <24 months with cystic fibrosis

Exclusion criteria

• patient >24 months

Trial design

25 participants in 1 patient group

cystic fibrosis infants

Other group

Description:

1 year follow-up in CF infants

Treatment:

Other: Physical assessment